Abstract
Chronic widespread pain (CWP) remains challenging due to its heterogenous causes and complex mechanisms. We analysed 2,923 plasma proteins from 29,254 UK Biobank participants. We first identified 811 proteins correlated with the presence of CWP cross- sectionally. We then created a sparse (top 10 proteins) and intricate (all significant proteins) proteomic-based score (ProtS) for CWP, both outperforming and improving the traditional clinical score (AUC: 0.82 and 0.88 vs 0.81 individually, and 0.87 and 0.92 in combination). Prospectively, the ProtS was associated with increased risks of a spectrum of pain traits, including dimensions from pain onset, progression and intensity, up to 13-years of follow-up; More importantly, we identified distinct proteomic signatures for nociplastic pain compared to nociceptive and neuropathic pain. For the individual proteins, carbonic anhydrase 14 (CA14) and leptin appeared as promising casual CWP biomarkers as triangulated by Mendelian randomisation and colocalization analyses. Lastly, our drug-repurposing analysis identified ten potential candidates for CWP therapies, calling for further research including randomised controlled trials. Although no CA14 agonists are currently available, CA14 remains a promising target, warranting further efforts to explore its role in pain modulation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DPA and JX received partial support from the Oxford National Institute for Health and care Research (NIHR) Biomedical Research Centre. The present study was supported by China National Natural Science Foundation of China (Grant 82103865 and 82373593 to Yanhui Dong) and Natural Science Foundation of Beijing (Grant 7222244 to Yanhui Dong), Peking University Talent Introduction Program Project (BMU2023YJ011 to Yanhui Dong).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵& Joint senior authorship
Data Availability
All data produced in the present study are available upon reasonable request to the authors
